Black Diamond Therapeutics (BDTX) Non-Current Assets (2018 - 2026)

Black Diamond Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• Quarterly Non-Current Assets fell 51.59% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.9 million (down 32.75% YoY) and the FY2025 annual result came in at $10.6 million, down 50.75% from the prior year.
• Non-Current Assets was $10.0 million for Q1 2026 at Black Diamond Therapeutics, down from $10.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $31.2 million in Q1 2022 and bottomed at $10.0 million in Q1 2026.
• A 5-year average of $23.2 million and a median of $23.7 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 95.94% — and 2026, when it plunged 51.59%.
• Black Diamond Therapeutics' Non-Current Assets stood at $28.5 million in 2022, then retreated by 14.07% to $24.5 million in 2023, then decreased by 12.51% to $21.5 million in 2024, then slumped by 50.75% to $10.6 million in 2025, then declined by 5.82% to $10.0 million in 2026.
• Business Quant data shows BDTX's Non-Current Assets at $10.0 million in Q1 2026, $10.6 million in Q4 2025, and $18.7 million in Q3 2025.